Abstract:Rapamycin is a triene macrolide antibiotic produced by Streptomyces hygroscopicus. Besides its wide application as an effective immunosuppressive agent, other important bioactivities have made rapamycin a potential drug lead for novel pharmaceutical development. However, the low titer of rapamycin in the original producer strain limits further industrialization efforts and restricts its use for other applications. Predicated on knowledge of the metabolic pathways related to rapamycin biosynthesis in S. hygroscopicus, we have rationally designed approaches to generate a rapamycin high producer strain of S. hygroscopicus HD-04-S. These have included alleviation of glucose repression, improved tolerance towards lysine and shikimic acid, and auxotrophy of tryptophan and phenylalanine through the application of stepwise UV mutagenesis. The resultant strain produced rapamycin at 450 mg/L in the shake flask scale. These fermentations were further scaled up in 120 and 20,000 L fermentors, respectively, at the pilot plant. Selected fermentation factors including agitation speed, pH, and on-line supplementation were systematically evaluated. A fed-batch strategy was established to maximize rapamycin production. With these efforts, an optimized fermentation process in the larger scale fermentor was developed. The final titer of rapamycin was 812 mg/L in the 120 L fermentor and 783 mg/L in the 20,000 L fermentor. This work highlights a high rapamycin producing strain derived by mutagenesis and subsequent screening, fermentation optimization of which has now made it feasible to produce rapamycin on an industrial scale by fermentation. The strategies developed here should also be applicable to titer improvement of other important microbial natural products on an industrial scale. Biotechnol. Bioeng. 2010; 107: 506-515. (C) 2010 Wiley Periodicals, Inc.

Scalable synthesis of bryostatin 1 and analogs, adjuvant leads against latent HIV

Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications

Total synthesis of bryostatin 3

Generation of high rapamycin producing strain via rational metabolic pathway-based mutagenesis and further titer improvement with fed-batch bioprocess optimization.

In vivo activation of latent HIV with a synthetic bryostatin analog effects both latent cell "kick" and "kill" in strategy for virus eradication

Identifying bryostatins and potential precursors from the bryozoan Bugula neritina

Cytotoxic Bryostatin Derivatives from the South China Sea Bryozoan Bugula Neritina

Bioactive Staurosporine Derivatives from the Streptomyces Sp. NB-A13.

Discovery and Synthesis of Novel Beesioside I Derivatives with Potent Anti-Hiv Activity.

Synthetic studies of antitumor natural products superstolides A and B. Construction of C20-C26 fragment of superstolide A.

The chemistry and biology of the bryostatins: potential PKC inhibitors in clinical development.

Design, Synthesis and Biological Evaluation of Novel Non-peptide Boronic Acid Derivatives As Proteasome Inhibitors

Bryostatin-1 Decreases HIV-1 Infection and Viral Production in Human Primary Macrophages

Design and Synthesis of Acyclic Boronic Acid Arginase Inhibitors

Synthesis and Biological Characterization of a 17β Hydroxysteroid Dehydrogenase Type 10 (17β-HSD10) Inhibitor

Comprehensive Optimization of Precursor-Directed Production of BC194 by Streptomyces Rochei MB037 Derived from the Marine Sponge Dysidea Arenaria

Scalable total synthesis of a mycobactin T analogue utilizing a novel synthetic and protection strategy

Process Development of the BACE Inhibitors BI 1147560 BS and BI 1181181 MZ

Preclinical Optimization of gp120 Entry Antagonists as anti-HIV-1 Agents with Improved Cytotoxicity and ADME Properties through Rational Design, Synthesis, and Antiviral Evaluation

Development of a Scalable Synthesis Toward a KRAS G12C Inhibitor Building Block Bearing an All-Carbon Quaternary Stereocenter, Part 1: from Discovery Route to Kilogram-Scale Production

Development of A Large Scale Asymmetric Synthesis of the Glucocorticoid Agonist Bi 653048 Bs H3po4